Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-06
S
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Sharmin Khan's research focuses on multiple myeloma, investigating its impact on bone disease and tumor growth. Her work explores the molecular mechanisms underlying myeloma progression, including the roles of signaling pathways, gene expression, and cellular differentiation. Khan has studied the therapeutic effects of various agents, such as proteasome inhibitors like bortezomib, and the potential of mesenchymal stem cell cytotherapy and human placenta-derived adherent cells in preventing bone loss and suppressing myeloma growth.
Her investigations also delve into specific molecular targets, including the ephrinB2/EphB4 axis and Bruton's tyrosine kinase, examining their involvement in myeloma cell migration and bone disease induction. Furthermore, Khan has examined the enzymatic activity of NAMPT/PBEF1 in relation to myeloma cell growth and osteoclast activity, as well as the consequences of parathyroid hormone administration on myeloma progression and bone integrity. Her recent work has explored targeting Notch inhibitors within the myeloma bone marrow niche to decrease tumor growth and bone destruction.
Metrics
- h-index: 12
- Publications: 95
- Citations: 675
Selected Publications
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma (2025)
Collaboration Network
Top Collaborators
Shmuel Yaccoby
University of Arkansas for Medical Sciences
34 shared publications
In database
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 34 shared publications
Wen Ling
University of Arkansas for Medical Sciences
33 shared publications
In database
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 33 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
25 shared publications
In database
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
Showing 5 of 25 shared publications
Xin Li
University of Arkansas for Medical Sciences (US)
24 shared publications
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 24 shared publications
Rakesh Bam
University of Arkansas for Medical Sciences (US)
16 shared publications
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow
- GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts
- Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease
Showing 5 of 16 shared publications
Joshua Epstein
University of Arkansas for Medical Sciences (US)
15 shared publications
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells
Showing 5 of 15 shared publications
Angela Pennisi
University of Arkansas for Medical Sciences (US)
14 shared publications
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
Showing 5 of 14 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
14 shared publications
In database
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
- Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
Showing 5 of 14 shared publications
Hayley M. Sabol
University of Arkansas for Medical Sciences
14 shared publications
In database
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 14 shared publications
Jesús Delgado‐Calle
University of Arkansas for Medical Sciences
13 shared publications
In database
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 13 shared publications
Sathisha Upparahalli Venkateshaiah
University of Arkansas for Medical Sciences (US)
12 shared publications
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts
- Stearoyl CoA Desaturase 1 (SCD1) Is Upregulated in Rapidly Growing Myeloma Cells and Is Required for Cell Proliferation,
- Abstract 1648: Primary myeloma plasma cells are capable of growth in adult, normal whole human bone marrow environment .
Showing 5 of 12 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
12 shared publications
In database
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 12 shared publications
Aric Anloague
University of Arkansas for Medical Sciences
12 shared publications
In database
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 12 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
9 shared publications
In database
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 9 shared publications
Frank H. Ebetino
BioVinc (United States) (US)
9 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics
Aric Anloague
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Disease Mechanisms Research
Charles P. Mercado
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Jesús Delgado‐Calle
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer-related molecular mechanisms research
Hayley M. Sabol
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Disease Mechanisms Research
Wen Ling
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Disease Mechanisms Research
Jin‐Ran Chen
University of Arkansas at Fayetteville
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer-related molecular mechanisms research